Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exjade after allogeneic hematopoietic cell transplantation for iron overload
2006-003970-89Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in iron overload, sponsored by Novartis. Primary endpoint: Change from baseline in serum ferritin at week 52. Started Sep 2007; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on 2006-003970-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003970-89.